PanelApp
Panels
Genes and Entities
Activity
Log in
Register
Genes and Genomic Entities
drug-efficacy
0 genes and genomic entities tagged
“drug-efficacy”
Find a gene or genomic entity
Gene or Genomic Entity Name
Enter a gene symbol, STR name, Region name, or the beginning of one, eg “CD” or “CD19”
0 genes and genomic entities
Show
Genes
STRS
Regions
Tagged
adult-onset
adverse-drug-reaction
age-specific-variation
anticipation
Autism Spectrum Disorder
CBLIF
CFAP298
CFAP300
chimeric-gene
clinical_reviewed
cnv
curated_removed
curated-variant-list
currently-ngs-unreportable
CYBC1
deletions
de novo
DIFF
differe
different_gene_name
digenic
discretionary
disputed
DNAAF11
DNAAF6
dominant-negative
drug-contraindication
drug-dosing
drug-efficacy
drug-indication
drug-toxicity
early-onset
ensembl_ids_known_missing
epigenetics
for-review
founder-effect
G6PC1
GBA1
gene-checked
gene_duplication
gene-duplication
gene-therapy-trial
GOF
GOF/LOF
HJV
IARS1
internal_inclusion_list_only
LARS1
limit of detection for heteroplasmic variants is not validated for WGS testing
locus-type-phenotype-only
locus-type-pseudogene
locus-type-rna-long-non-coding
locus-type-rna-micro
locus-type-rna-misc
locus-type-rna-ribosomal
locus-type-rna-small-nuclear
locus-type-rna-transfer
locus-type-rna-vault
locus-type-small-nucleolar
locus-type-unknown
LOF/dominant-negative
MARS1
microdeletion
microduplication
missense
MMUT
monogenic - polygenic
monogenic-polygenic
mosaicism
multifactorial
new-
new-gene-name
ngs-false-positive-region
NGS Not Validated
non-coding-known-pathogenic
nucleotide-repeat-expansion
ODAD1
ODAD2
ODAD3
ODAD4
pathogenic-synonymous
pharmacogenetics
polygenic
prognosis
promoter
Pseudoautosomal region 1
Pseudoautosomal region 2
Q1_22_expert_review
Q1_22_MOI
Q1_22_NHS_review
Q1_22_phenotype
Q1_22_rating
Q1_234
Q1_23_demote_amber
Q1_23_demote_grey
Q1_23_demote_red
Q1_23_expert_review
Q1_23_MOI
Q1_23_MOP_not_LOF
Q1_23_MOP_other
Q1_23_NHS_review
Q1_23_promote_green
Q1_24_demote_amber
Q1_24_demote_red
Q1_24_expert_review
Q1_24_MOI
Q1_24_NHS_review
Q1_24_phenotype
Q1_24_promote_green
Q2_21_expert_review
Q2_21_MOI
Q2_21_NHS_review
Q2_21_phenotype
Q2_21_rating
Q2_22_expert_review
Q2_22_MOI
Q2_22_NHS_review
Q2_22_phenotype
Q2_22_rating
Q2_23_demote_amber
Q2_23_demote_grey
Q2_23_demote_red
Q2_23_expert_review
Q2_23_MOI
Q2_23_NHS_review
Q2_23_promote_green
Q2_24_demote_amber
Q2_24_demote_red
Q2_24_expert_review
Q2_24_MOI
Q2_24_NHS_review
Q2_24_promote_green
Q3_21_expert_review
Q3_21_MOI
Q3_21_NHS_review
Q3_21_phenotype
Q3_21_rating
Q3_22_expert_review
Q3_22_MOI
Q3_22_NHS_review
Q3_22_phenotype
Q3_22_rating
Q3_23_demote_amber
Q3_23_demote_red
Q3_23_expert_review
Q3_23_MOI
Q3_23_NHS_review
Q3_23_phenotype
Q3_23_promote_green
Q4_21_expert_review
Q4_21_MOI
Q4_21_NHS_review
Q4_21_phenotype
Q4_21_rating
Q4_22_demote_amber
Q4_22_demote_grey
Q4_22_demote_red
Q4_22_expert_review
Q4_22_MOI
Q4_22_MOP_not_LOF
Q4_22_MOP_other
Q4_22_NHS_review
Q4_22_promote_green
Q4_23_demote_amber
Q4_23_demote_red
Q4_23_expert_review
Q4_23_MOI
Q4_23_NHS_review
Q4_23_promote_green
Q4_24_expert_review
recurrent-variant
refuted
regulatory-region
removed
SARS1
Schizophrenia
single-deletion
Skewed X-inactivation
SKIC2
SKIC3
somatic
special_caller_only
STR
stratified-medicine
structural-variant
sva
TAFAZZIN
to_be_confirmed_NHSE
treatable
trinucleotide-repeat-expansion
watchlist
watchlist_moi
x-linked-over-dominance
y-chromosome